Table 1.
Protein subunit vaccines, curent clinical phases
| Vaccines types | Strategy of design | Clinical phase |
|---|---|---|
| SARS-CoV-2 rS/Matrix M1-Adjuvant | (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with Matrix M) | Phase 2 and 3 |
| Recombinant SARS-CoV-2 vaccine | (CHO Cell) | Phase 2 and 3 |
| SCB-2019 + AS03 or CpG 1018 adjuvant | (Native like Trimeric subunit Spike Protein vaccine) plus Alum adjuvant | phase 3 |
| COVAX-19® | Recombinant spike protein + adjuvant | Phase 1/2 |
| MF59 | Adjuvanted SARS-CoV-2 Sclamp vaccine | Phase 2 |
| MVC-COV1901 | (Spike-2P protein + adjuvant CpG 1018) | Phase 1/2 and Phase 2 |
| FINLAY-FR1 anti-SARS-CoV-2 Vaccine | (RBD + adjuvant) | Phase 1/2 and Phase 2 |
| FINLAY-FR-2 anti-SARS-CoV-2 Vaccine | (RBD chemically conjugated to tetanus toxoid plus adjuvant) | Phase 2 and 3 |
| EpiVacCorona | (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | Phase 2 and 3 |
| Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | Phase 2 |
| IMP CoVac-1 | (SARS-CoV-2 HLA-DR peptides) | Phase 1 |
| UB-612 | (Multitope peptide based S1-RBD-protein based vaccine) | Phase 2 and 2/3 |
| AdimrSC-2f | (Recombinant RBD +/− Aluminium) | Phase 1 |
| CIGB-669 | (RBD+AgnHB) | Phase 1/2 |
| CIGB-66 | (RBD+aluminium hydroxide) | Phase 1/2 and phase 3 |
| Recombinant Sars-CoV-2 vaccine | Spike protein, Aluminum adjuvant | Phase 1/2 |
| Recombinant protein vaccine S-268019 | (Using Baculovirus expression vector system) | Phase 1/2 |
| SARS-CoV-2-RBD-Fc fusion protein | Phase 1/2 | |
| COVAC-1 and COVAC-2 sub-unit vaccine | (Spike protein) + SWE adjuvant | Phase 1/2 |
| GBP510 | A recombinant surface protein vaccine with adjuvant AS03 (Aluminium hydroxide) | Phase 1/2 |
| Razi Cov Pars | Recombinant spike protein | Phase 1 |
| MF59 | Adjuvanted SARS-CoV-2 Sclamp vaccine | Phase 1 |
| SpFN (spike ferritin nanoparticle) | Uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant | Phase 1 |
| EuCorVac-19 | A spike protein using the recombinant protein technology and with an adjuvant | Phase 1/2 |
| ReCOV | Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell) | Phase 1 |
| Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Fusion Protein Vaccine | Phase 2 |
Source: ClinicalTrials.gov website; WHO.